Healthcare | February 21, 2025
KIMS enters into agreement to manage Splendid Hospitals, Hyderabad
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated
The inspection was successfully completed
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
the inspection conducted from January 27 to January 31, 2025
The Alathur facility specializes in the production of Cephalosporin antibiotics
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
Subscribe To Our Newsletter & Stay Updated
